Stocks in play: Mindset Pharma Inc.

Today provided a recap of its 2021 milestones and highlights. “In 2021, we made significant progress in building our portfolio of next-generation psychedelic compounds showing improved preclinical safety and efficacy of 5-MeO-DMT and psilocybin-based therapies,” said James Lanthier, CEO of Mindset. Operational Highlights include an Expanded Patent Portfolio, an Advanced First Lead Drug Candidate Toward Clinical Trials, Effect Size & Safety Differentiation Driven by Technology Platform. Mindset Pharma Inc. shares C.MSET are trading up 0.03 cents at $0.85.

Read:

• As Crypto Mining Undergoes a Sustainable Renaissance, Newer, Greener Operations Arise

• Oncology Drug Developers Looking at Significant Projected Growth Through 2030

• Plant-Based Meats Continue to Sprout Growing Revenues on Year-Over-Year Basis

• No Apparent Need to Panic Over Omicron as Vaccine Developers Are on the Case

• Plant-Based Meats Market Projected to Hit $162 Billion by 2030, as New Products Launch